Posters/Publications

oral

Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis

Keystone Symposia

Date - 02/2025
poster

Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study

Keystone Symposia

Date - 02/2025
oral

FASN inhibitor

MASH TAG

Date - 01/2025
poster

Denifanstat showed anti-fibrotic effect both on conventional and digital pathology in a metabolic dysfunction-associated steatohepatitis (MASH) Phase 2b trial (FASCINATE-2)

MASH TAG

Date - 01/2025
oral

AI-Based Digital Pathology Shows that Denifanstat Improves Multiple Parameters of Fibrosis and Reduces Progression to Cirrhosis in MASH patients with F2/F3

AASLD The Liver Meeting

Date - 11/2024
poster

Denifanstat significantly improves liver fibrosis in difficult-to-treat MASH patients – Results from conventional and AI-based pathology from the phase 2b FASCINATE-2, a 52-week randomized, double-blind, placebo-controlled trial

AASLD The Liver Meeting

Date - 11/2024
poster

Fatty acid synthase (FASN) inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH

AASLD The Liver Meeting

Date - 11/2024
paper

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

The Lancet Gastroenterology & Hepatology

Date - 10/2024
oral

Demonstrating denifanstat’s differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity

8th Annual MASH Drug Development Summit

Date - 09/2024
poster

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH

EASL International Liver Congress

Date - 06/2024
Site map
Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

Scroll to Top